Stockscreener 앱 받기
0.501
1.96%
-0.01
시장 영업 전:
.52
0.019
+3.79%
Oragenics Inc 주식(OGEN)의 최신 뉴스
Oragenics Inc. Revenue Breakdown – AMEX:OGEN - TradingView
Oragenics Inc (OGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oragenics Inc (OGEN) Cash Flow - TradingKey
OGEN|Oragenics Inc|Price:0.507|Chg%:-0.004 - TradingKey
TradingKey - TradingKey
Oragenics Inc (OGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oragenics Inc. (OGEN) Holds Near Support Amid Modest DeclineBPI Bear Correction - dars.gov.et
Oragenics Incto Receive Exclusive License - Moomoo
Form 4 Oragenics Inc For: 7 July By Investing.com - Investing.com Nigeria
Oragenics (OGEN) CFO receives 55,900 stock options at $0.59 exercise price - Stock Titan
ORAGENICS (OGEN) CFO reports initial holdings, including 10,000-share stock option grant - Stock Titan
Oragenics Activates All Australian Phase IIa Trial Sites for Concussion Drug ONP-002 - citybuzz -
Oragenics Achieves Full Activation of Australian Phase IIa Trial NetworkAll Three Sites Now Enrolling - The Manila Times
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling - GlobeNewswire
Oragenics Appoints New Chief Financial Officer and Leader - TipRanks
Oragenics, Inc. Announces Appointment of John Spencer to Chief Financial Officer, Effective July 1, 2026 - marketscreener.com
Price to earnings forward of Oragenics Inc. – AMEX:OGEN - TradingView
OGEN Q2 2023 Earnings: Narrowed Loss Surpasses Estimates, Stock Declines Amid No RevenueEarnings Quality Analysis - DonanımHaber
Price to book forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to EBIT forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to revenue forward of Oragenics Inc. – AMEX:OGEN - TradingView
OGEN Q2 2023 Earnings: Significant EPS Beat Amidst No Revenue ReportedGuidance vs Actual - dars.gov.et
Oragenics Inc (OGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oragenics, Inc. Actuals & Estimates (AMEX:OGEN) - TradingView
Oragenics (OGEN) Sees Minor Pullback as Biotech Stock Holds Above Key SupportMA Cross Alert - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beat as Operating Loss NarrowsEarnings Deceleration Risk - dars.gov.et
Oragenics Inc (OGEN) Institutional Confidence - TradingKey
Oragenics Inc. (OGEN) Holds Near $0.59 Support Amid Low Volatility – Key Levels in FocusLeading Diagonal - DonanımHaber
OGENOragenics Inc Short Interest - Finviz
OGEN Q2 2023 Earnings: Narrower-than-Expected Loss Boosts Investor Sentiment Despite Stock DeclineEnergy Earnings Report - dars.gov.et
Oragenics Inc (OGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oragenics Inc (OGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oragenics Inc (OGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oragenics Inc (OGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oragenics Inc (OGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OGEN Q2 2023 Earnings: EPS Beat Despite No Revenue, Stock DeclinesEarnings Yield Spread - newsline.com
OGEN Q2 2023 Earnings: EPS Beat on Lower-than-Expected Loss, But Stock DeclinesEarnings Volatility Report - newsline.com
OGEN Q2 2023 Earnings: Loss Narrower Than Expected but No Revenue, Stock DeclinesQuarterly Earnings Report - newsline.com
OGEN Q2 2023 Earnings: Narrower Loss Drives 5% Bounce on Surprise BeatRevenue Growth Report - newsline.com
Oragenics Inc. (OGEN) Gains Ground: Potential Breakout Above $0.65 in Sight?Swing Trade Setups - newsline.com
OGEN Q2 2023 Earnings: Smaller-Than-Expected Loss as Clinical Pipeline ProgressesProduct Revenue Analysis - newsline.com
Oragenics Inc. (OGEN) Edges Lower to $0.60, Testing Key Support LevelsEarnings Quality Factor - newsline.com
OGEN Q2 2023 Earnings: EPS Beats Estimates by Over 50% as Company Advances PipelineBanking Earnings Report - newsline.com
ORAGENICS INC (OGEN) Stock Chart - ChartMill
OGEN Q2 2023 Earnings: Narrower-than-expected loss as EPS beats estimates by over 50%Annual Earnings Summary - dars.gov.et
Oragenics Inc. (OGEN) Inches Higher as Stock Tests Key Resistance Near $0.64SuperTrend Flip - newsline.com
OGEN Q2 2023 Earnings: EPS Surprise Beats Estimates Amid No Revenue, Cash Burn ConcernsEarnings Preview - DonanımHaber
Oragenics Inc. (OGEN) Slips Amid Low Volume, Hovers Near Key SupportIceberg Order - newsline.com
Oragenics Inc. (OGEN) Edges Higher as Biotech Volatility PersistsIceberg Order - The Legal Advocate
OGEN Q2 2023 Earnings: Narrower-than-Expected Loss Boosts Investor SentimentOpen Signal Network - Newser
OGEN | Oragenics Inc. Executive Compensation - Quiver Quantitative
Oragenics Q2 2023 Earnings: Narrowing Loss Surprises, No Revenue YetFull Year Guidance - Newser
OGEN News | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
1.97%
0.83%
자본화:
|
볼륨(24시간):